Q-LINE BIOTECH LIMITED Financial Ratios
QLINE · Healthcare · Current price ₹598
P/E ratio
17.5x
P/B ratio
3.4x
ROE
25.9%
ROCE
22.0%
Debt / Equity
0.91
Dividend yield
0.0%
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | 17.5x | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | 3.4x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | 25.9% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | 22.0% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | 0.91 | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with Q-LINE BIOTECH LIMITED's latest numbers.
Q-LINE BIOTECH LIMITED profitability
Q-LINE BIOTECH LIMITED generates a return on equity of 25.9% and a return on capital employed of 22.0%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of 0.91 and a P/E of 17.5x, Q-LINE BIOTECH LIMITED is moderately leveraged. Our overall business-quality score for the company is 6.3 / 10.
Understand the ratios
More on Q-LINE BIOTECH LIMITED
DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.